Recherche

Afficher tous les résultats pour

Accueil

Personne

Gerardo Turcatti

À propos
Confidentialité
Mentions légales

Graph Chatbot

Publications associées (56)

Marker-Free Automatic Quantification of Drug-Treated Cardiomyocytes with Digital Holographic Imaging

Gerardo Turcatti, Pierre Marquet, Benjamin Rappaz, Fabien Kuttler, Bokyoung Kim

We use quantitative phase digital holographic microscopy (QP-DHM) to image and quantify the beating movement of cardiomyocytes, derived from induced pluripotent stem cells (iPSCs), in control and drug-treated conditions. The development of an analysis algo ...

AMER CHEMICAL SOC2020

A high-content image-based drug screen of clinical compounds against cell transmission of adenovirus

Gerardo Turcatti, Fabien Kuttler

Human adenoviruses (HAdVs) are fatal to immuno-suppressed individuals, but no effective anti-HAdV therapy is available. Here, we present a novel image-based high-throughput screening (HTS) platform, which scores the full viral replication cycle from virus ...

2020

High-throughput automated organoid culture via stem-cell aggregation in microcavity arrays

Gerardo Turcatti, Matthias Lütolf, Nathalie Brandenberg, Fabien Kuttler, Krisztian Homicsko, Nikolche Gjorevski, George Coukos, Camilla Carla Alma Ceroni

Stem-cell-derived epithelial organoids are routinely used for the biological and biomedical modelling of tissues. However, the complexity, lack of standardization and quality control of stem cell culture in solid extracellular matrices hampers the routine ...

NATURE PUBLISHING GROUP2020

Macrocycle synthesis strategy based on step-wise “adding and reacting” three components enables screening of large combinatorial libraries

Gerardo Turcatti, Jonathan Patrice Vesin, Christian Heinis, Alessandro Angelini, Alessandro Zorzi, Julien Bortoli Chapalay, Sangram Shivdas Kale, Kaycie Marie Butler, Ganesh Kumar Mothukuri, Carl Leonard Stenbratt

Macrocycles provide an attractive modality for drug development, but generating ligands for new targets is hampered by the limited availability of large macrocycle libraries. We have established a solution-phase macrocycle synthesis strategy in which three ...

2020

Image-Based Marker-Free Screening of GABA(A) Agonists, Antagonists, and Modulators

Gerardo Turcatti, Pierre Marquet, Damiano Banfi, Pascal Jourdain, Benjamin Rappaz, Fabien Kuttler

The ionotropic GABA(A) receptors represent the main target for different groups of widely used drugs having hypnotic and anxiolytic effects. So far, most approaches used to assess GABA activity involve invasive low -throughput electrophysiological techniqu ...

2019

Screening-based approach to discover effective platinum-based chemotherapies for cancers with poor prognosis

Gerardo Turcatti, Damiano Banfi, Paul Joseph Dyson, Fabien Kuttler, Hristo Plamenov Varbanov

Drug combinations are extensively used to treat cancer and are often selected according to complementary mechanisms. Here, we describe a cell-based high-throughput screening assay for identification of synergistic combinations between broadly applied plati ...

2019

Thiol-to-amine cyclization reaction enables screening of large libraries of macrocyclic compounds and the generation of sub-kilodalton ligands

Gerardo Turcatti, Jonathan Patrice Vesin, Christian Heinis, Van Manh Pham, Julien Bortoli Chapalay, Sangram Shivdas Kale, Xudong Kong, Milan Bergeron-Brlek, Patrick Andreas Gonschorek, João Miguel Franco Machado

Macrocyclic compounds are an attractive modality for drug development, but the limited availability of large, structurally diverse macrocyclic libraries hampers the discovery of leads. Here, we describe the discovery of efficient macrocyclization reactions ...

2019

A Universal Assay for Aminopeptidase Activity and Its Application for Dipeptidyl Peptidase-4 Drug Discovery

Gerardo Turcatti, Marc Chambon, Jonathan Patrice Vesin, Elena Goun, Arkadiy Bazhin, Julien Bortoli Chapalay, James William Collins

Aminopeptidases, such as dipeptidyl peptidase 4 (DPP-4, CD26), are potent therapeutic targets for pharmacological interventions because they play key roles in many important pathological pathways. To analyze amino-peptidase activity in vitro (including hig ...

AMER CHEMICAL SOC2019

Quantification of stored red blood cell fluctuations by time-lapse holographic cell imaging

Gerardo Turcatti, Pierre Marquet, Michel Prudent, Benjamin Rappaz, Manon Sandra Bardyn

We propose methods to quantitatively calculate the fluctuation rate of red blood cells with nanometric axial and millisecond temporal sensitivity at the single-cell level by using time-lapse holographic cell imaging. For this quantitative analysis, cell me ...

2018

High-throughput, nonperturbing quantification of lipid droplets with digital holographic microscopy

Gerardo Turcatti, Olaia Maria Naveiras Torres-Quiroga, Vasco Ledebur de Antas de Campos

American Society for Biochemistry and Molecular Biology Inc.2018

Targeting STING with covalent small-molecule inhibitors

Gerardo Turcatti, Luc Reymond, Françoise Gisou van der Goot Grunberg, Laurence Gouzi Abrami, Andrea Ablasser, Muhammet Fatih Gülen, Simone Margret Haag, Michael Christian Heymann, Alexiane Clara Decout

2018

Red blood cells ageing markers: a multi-parametric analysis

Gerardo Turcatti, Michel Prudent, Niels Erik Lion, Benjamin Rappaz, Manon Sandra Bardyn, David Crettaz

Background. Red blood cells collected in citrate-phosphate-dextrose can be stored for up to 42 days at 4 degrees C in saline-adenine-glucose-mannitol additive solution. During this controlled, but nevertheless artificial, ex vivo ageing, red blood cells ac ...

Simti Servizi Srl2017

Repositioning approved drugs for the treatment of problematic cancers using a screening approach

Gerardo Turcatti, Damiano Banfi, Paul Joseph Dyson, Fabien Kuttler, Hristo Plamenov Varbanov

Advances in treatment strategies together with an earlier diagnosis have considerably increased the average survival of cancer patients over the last four decades. Nevertheless, despite the growing number of new antineoplastic agents introduced each year, ...

2017

Development Of A Novel First-In-Class Oral Inhibitor Of The Notch Pathway

Gerardo Turcatti, Freddy Radtke, Rajwinder Lehal, Viktoria Reinmüller

Ferrata Storti Foundation2016

Screening out irrelevant cell-based models of disease

Gerardo Turcatti

The common and persistent failures to translate promising preclinical drug candidates into clinical success highlight the limited effectiveness of disease models currently used in drug discovery. An apparent reluctance to explore and adopt alternative cell ...

Nature Publishing Group2016

Wnt directs the endosomal flux of LDL-derived cholesterol and lipid droplet homeostasis

Gerardo Turcatti, Marc Chambon, Nicolas Jean Philippe Guex, Olivier Martin

The Wnt pathway, which controls crucial steps of the development and differentiation programs, has been proposed to influence lipid storage and homeostasis. In this paper, using an unbiased strategy based on high-content genome-wide RNAi screens that monit ...

Nature Publishing Group2015

Automated multi-parameter measurement of cardiomyocytes dynamics with digital holographic microscopy

Gerardo Turcatti, Pierre Marquet, Benjamin Rappaz

Compounds tested during drug development may have adverse effects on the heart; therefore all new chemical entities have to undergo extensive preclinical assessment for cardiac liability. Conventional intensity-based imaging techniques are not robust enoug ...

Optical Society of America2015

Identification of CDC-48 inhibitors in C. elegans

Gerardo Turcatti, Marc Chambon

Wiley-Blackwell2015

Developing the Biomolecular Screening Facility at the EPFL into the Chemical Biology Screening Platform for Switzerland

Gerardo Turcatti

The Biomolecular Screening Facility (BSF) is a multidisciplinary laboratory created in 2006 at the Ecole Polytechnique Federale de Lausanne (EPFL) to perform medium and high throughput screening in life sciences-related projects. The BSF was conceived and ...

Bentham Science Publishers2014

Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors

Gerardo Turcatti, Marc Chambon, Pierre Vogel, Olivier Michielin, Somi Reddy Majjigapu

Indoleamine 2,3-dioxygenase 1 (IDO1) is a key regulator of immune responses and therefore an important therapeutic target for the treatment of diseases that involve pathological immune escape, such as cancer. Here, we describe a robust and sensitive high-t ...

Elsevier France-Editions Scientifiques Medicales Elsevier2014

Page 2 sur 3